PUBLIC COMPANY
savePFIZER
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
- phase3A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
- phase3A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- phase3A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
- phase3A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- phase3Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- —A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B
- phase1A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
🐶 Hiring Signal
News
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 4h ago
- 9 biotechs will cut at least half their California workforcesWorkforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…biospace · 14h ago
- Pfizer leaps into ‘in vivo’ CAR-T with latest China dealThe potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.biopharma_dive · 1d ago
- Government actions are hitting smaller biotechs the hardest: ReportLayoffs at the FDA, disruptions to research funding and increased tariffs led the investment banking firm Cassel Salpeter to wonder whether the government is strangling the biotech industry.biospace · 1d ago
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 1d ago
- Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B dealThe Chinese biotech will work with Pfizer on three in vivo CAR T therapies for autoimmune indications.biospace · 1d ago
- In China’s shadow, Pfizer CEO calls for AI savings to bolster Big PharmaSpeaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.biospace · 1d ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetySummit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.biospace · 1d ago
- Pfizer gets into in vivo CAR-T through licensing deal with Starna TherapeuticsPfizer is entering the in vivo CAR-T race, paying $330 million upfront to Starna Therapeutics. The deal gives Pfizer exclusive rights outside of Greater China to three pre-IND assets in autoimmune…endpoints · 1d ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
comments(0)
5-min edit window · permanent after that